SELENON

Across TCGA pan-cancer cohorts, SELENON mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SELENON data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SELENON mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SELENON expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where SELENON mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.960	0.736	.005	18	view →
PDAC	DFS	Median	IV	0.250	0.785	.010	14	view →
CCRCC	DFS	Quartile	III,IV	0.482	0.932	.024	7	view →
LSCC	DFS	Quartile	All	0.517	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SELENON–HNSC (DFS)

Open the HNSC breakdown →